PRODUCT DESCRIPTION:

Favipiravir Tablets are broad-spectrum antiviral agents designed to inhibit viral RNA-dependent RNA polymerase, a key enzyme responsible for viral replication.

Originally developed for resistant influenza strains, Favipiravir has shown promise in treating a range of RNA viruses, including in emergency use during outbreaks such as COVID-19.

Offered in strengths of 200 MG and 400 MG, these tablets are especially valuable for stockpiling in public health emergencies, pandemic preparedness programs, and hospital protocols for severe viral respiratory infections.

Manufactured under strict regulatory compliance, Favipiravir is trusted by governments and global health organizations for rapid deployment when speed and efficacy matter most.

Formulation & Presentation:

• Dosage Form: Tablets
• Presentation: Available in Blister Pack or HDPE Bottle (As per market requirement)
• Available Strengths:
  • Favipiravir Tablets: 200 MG
  • Favipiravir Tablets: 400 MG
• Route of Administration: Oral (As per physician’s discretion or therapeutic indication)

Therapeutic Indications:

• Treatment of mild to moderate influenza in adults
• Emergency use in respiratory RNA virus infections, including COVID-19 (as per national protocols)
• Considered for use during viral outbreaks under regulatory approvals

Side Effects:

• COMMON:
  • Elevated liver enzymes
  • Diarrhea
  • Decreased neutrophil count
  • Increased uric acid levels
  • Gastrointestinal discomfort
• SERIOUS (RARE):
  • Teratogenicity (contraindicated in pregnancy)
  • QT interval prolongation (cardiac monitoring advised in at-risk patients)
  • Acute hypersensitivity reactions
  • Hepatic toxicity (in prolonged use)
• PRECAUTIONS:
  • Strictly contraindicated in pregnancy and lactation
  • Liver function and uric acid levels must be monitored during treatment
  • Not recommended in patients with severe hepatic or renal impairment
  • Use only under supervision in emergency protocols or approved national programs

Avoid concomitant use with known QT-prolonging agents